Increasing use of 'party drugs' in people living with HIV on antiretrovirals: A concern for patient safety

AIDS

Volumn 29, Issue 13, 2015, Pages 1585-1592

  Bracchi, Margherita ^a   Stuart, David ^a   Castles, Richard ^b   Khoo, Saye ^c   Back, David ^c   Boffito, Marta ^a,d  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral agents; Drug interactions; HIV infection; MSM; Recreational drugs; Street drugs

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4' METHYLMETHCATHINONE; BENZODIAZEPINE; COCAINE; ILLICIT DRUG; KETAMINE; METHAMPHETAMINE; RECREATIONAL DRUG; SILDENAFIL; TADALAFIL; VARDENAFIL; ANTIRETROVIRUS AGENT; STREET DRUG;

CASE STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MEN WHO HAVE SEX WITH MEN; OBSERVATIONAL STUDY; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; ADVERSE DRUG REACTION; COMPLICATION; DRUG INTERACTION; HIV INFECTIONS;

ANTI-RETROVIRAL AGENTS; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; HUMANS; PATIENT SAFETY; STREET DRUGS;

EID: 84942531944     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000786     Document Type: Review

References (91)

1. Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med 1985; 103:755-759.
2. Kirby T, Thornber-Dunwell M. High-risk drug practices tighten grip on London gay scene. Lancet 2013; 381:101-102.
3. Daskalopoulou MRA, Philips A. Recreational drug use, poly-drug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV 2014; 1:e22-e31.
4. Theodore PS, Duran RE, Antoni MH. Drug use and sexual risk among gay and bisexual men who frequent party venues. AIDS Behav 2014; 18:2178-2186.
5. Colfax G, Guzman R. Club drugs and HIV infection: a review. Clin Infect Dis 2006; 42:1463-1469.
6. Stuart D. Sexualised drug use by MSM: background, current status and response. HIV Nursing 2013; 14:1415.
7. Smith KM, Larive LL, Romanelli F. Club drugs: methylenediox-ymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 2002; 59:1067-1076.
8. De Ryck I, Van Laeken D, Noestlinger C, Platteau T, Colebun-ders R. The use of erection enhancing medication and party drugs among men living with HIV in Europe. AIDS Care 2013; 25:1062-1066.
9. Li J, McDaid LM. Alcohol and drug use during unprotected anal intercourse among gay and bisexual men in Scotland: what are the implications for HIV prevention? Sex Transm Infect 2014; 90:125-132.
10. Grov C, Kelly BC, Parsons JT. Polydrug use among club-going young adults recruited through time-space sampling. Subst Use Misuse 2009; 44:848-864.
11. Stuart D, Colin S. ChemSex vs recreational drug use: a proposed definition for health workers. HIV Treatment Bulletin. May/June 2015 ed; 2015.
12. Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex 2001; 41:17-35.
13. Ostrow DG, Plankey MW, Cox C, Li X, Shoptaw S, Jacobson LP, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr 2009; 51:349-355.
14. Colfax GN, Mansergh G, Guzman R, Vittinghoff E, Marks G, Rader M, et al. Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr 2001; 28:373-379.
15. Rawstorne P, Digiusto E, Worth H, Zablotska I. Associations between crystal methamphetamine use and potentially unsafe sexual activity among gay men in Australia. Arch Sex Behav 2007; 36:646-654.
16. Rajasingham R, Mimiaga MJ, White JM, Pinkston MM, Baden RP, Mitty JA. A systematic review of behavioral and treatment outcome studies among HIV-infected men who have sex with men who abuse crystal methamphetamine. AIDS Patient Care STDS 2012; 26:36-52.
17. Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Strathdee SA, et al. Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy 2010; 21:347-358.
18. Kumar S, Rao P, Earla R, Kumar A. Drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol 2014; 11:1-13.
19. Romanelli F, Smith KM, Pomeroy C. Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Top HIV Med 2003; 11:25-32.
20. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002; 36:1598-1613.
21. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 2005; 46:79-87.
22. Pal D, Kwatra D, Minocha M, Paturi DK, Budda B, Mitra AK. Efflux transporters-and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci 2011; 88:959-971.
23. Staltari O, Leporini C, Caroleo B, Russo E, Siniscalchi A, De Sarro G, et al. Drug-drug interactions: antiretroviral drugs and recreational drugs. Recent Pat CNS Drug Discov 2014; 9:153-163.
24. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352:1751-1752.
25. Hales G, Roth N, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir Ther 2000; 5:19.
26. Baker R, Bowers M. Ritonavir and ecstasy. BETA 1997: 5.
27. Dargan PI, Sedefov R, Gallegos A, Wood DM. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 2011; 3:454-463.
28. Report UNOoDaCWD. United Nations Publication Sales No. E08XI1. 2008.
29. Shoptaw S, Reback CJ, Freese TE. Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. J Addict Dis 2002; 21:91-105.
30. Buchacz K, McFarland W, Kellogg TA, Loeb L, Holmberg SD, Dilley J, et al. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS 2005; 19:1423-1424.
31. Cook CE, Jeffcoat AR, Sadler BM, Hill JM, Voyksner RD, Pugh DE, et al. Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 1992; 20:856-862.
32. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wiel-ing J, Hekster YA, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2005; 78:664-674.
33. German P MA, Wei L, Murray B, Warren D, Kearney BP. The effect of cobicistat on cytochrome P450 2D6, 2B6 and P-glyco-protein using phenotypic probes. In: 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami; 2011.
34. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-537.
35. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388-397.
36. Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 1987; 42:278-282.
37. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000; 67:466-477.
38. Klitzman RL, Pope HG Jr, Hudson JI. MDMA ('Ecstasy') abuse and high-risk sexual behaviors among 169 gay and bisexual men. Am J Psychiatry 2000; 157:1162-1164.
39. Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med 1999; 16:194-197.
40. Steele TD, McCann UD, Ricaurte GA. 3, 4-Methylenedioxy-methamphetamine (MDMA, 'Ecstasy'): pharmacology and toxicology in animals and humans. Addiction 1994; 89:539-551.
41. Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs. Biochem Pharmacol 2000; 59:1563-1571.
42. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 2000; 112-113:133-142.
43. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (R/-)-3, 4-methylenedioxymethamphetamine ('Ecstasy') metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 2002; 63:2111-2119.
44. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharma-cology (Berl) 2011; 214:593-602.
45. Gregg RA, Rawls SM. Behavioral pharmacology of designer cathinones: a review of the preclinical literature. Life Sci 2014; 97:27-30.
46. Meyer MR, Wilhelm J, Peters FT, Maurer HH. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, bu-tylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010; 397:1225-1233.
47. Pedersen AJ, Reitzel LA, Johansen SS, Linnet K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 2013; 5:430-438.
48. Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care 2011; 38:41-58v-vi.
49. Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA 1996; 276:1580-1588.
50. LeDuc BW, Sinclair PR, Shuster L, Sinclair JF, Evans JE, Green-blatt DJ. Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. Pharmacology 1993; 46:294-300.
51. Perino LE, Warren GH, Levine JS. Cocaine-induced hepatotoxi-city in humans. Gastroenterology 1987; 93:176-180.
52. Wanless IR, Dore S, Gopinath N, Tan J, Cameron R, Heathcote EJ, et al. Histopathology of cocaine hepatotoxicity. Report of four patients. Gastroenterology 1990; 98:497-501.
53. Bornheim LM. Effect of cytochrome P450 inducers on cocaine-mediated hepatotoxicity. Toxicol Appl Pharmacol 1998; 150:158-165.
54. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen O, et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol 1994; 270:35-43.
55. Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S. An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 2011; 3:560-568.
56. Camacho A, Matthews SC, Dimsdale JE. Use of GHB compounds by HIV-positive individuals. Am J Addict 2004; 13:120-127.
57. Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004; 28:625-630.
58. Kohrs FP, Porter WH. gamma-Hydroxybutyrate intoxication and overdose. Ann Emerg Med 1999; 33:475-476.
59. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. Pediatrics 1997; 100:705-708.
60. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyro-lactone and 1, 4-butanediol. Clin Toxicol (Phila) 2012; 50: 458-470.
61. Kaufman EE, Nelson T. Evidence for the participation of a cytosolic NADPR-dependent oxidoreductase in the catabolism of gamma-hydroxybutyrate in vivo. J Neurochem 1987; 48:1935-1941.
62. Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352:2721-2732.
63. Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45:353-356.
64. Vayer P, Mandel P, Maitre M. Conversion of gamma-hydro-xybutyrate to gamma-aminobutyrate in vitro. J Neurochem 1985; 45:810-814.
65. Lettieri J, Fung HL. Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol 1976; 13:425-437.
66. McCambridge J, Winstock A, Hunt N, Mitcheson L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res 2007; 13:57-64.
67. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, et al. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001; 29:887-890.
68. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30:853-858.
69. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2010; 14:625-629.
70. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 2013; 4:24.
71. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008; 9:598-610.
72. Zhou J, Shaw SG, Gilleece Y. Dilated common bile duct and deranged liver function tests associated with ketamine use in two HIV-positive MSM. Int J STD AIDS 2013; 24:667-669.
73. Noppers I, Olofsen E, Niesters M, Aarts L, Mooren R, Dahan A, et al. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology 2011; 114:1435-1445.
74. Koppel C, Arndt I, Ibe K. Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. Eur J Drug Metab Pharma-cokinet 1990; 15:259-263.
75. Vijayaraghavan M, Freitas D, Bangsberg DR, Miaskowski C, Kushel MB. Nonmedical use of nonopioid psychotherapeutic medications in a community-based cohort of HIV-infected indigent adults. Drug Alcohol Depend 2014; 143: 263-267.
76. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, et al. Differential impairment of triazolam and zolpi-dem clearance by ritonavir. J Acquir Immune Defic Syndr 2000; 24:129-136.
77. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999; 19:293-296.
78. Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos 1997; 25:133-139.
79. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ, et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26:1155-1166.
80. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 1998; 18:256.
81. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debriso-quin, hydroxylation phenotype. Clin Pharmacol Ther 1989; 45:348-355.
82. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52:160-169.
83. Chu PL, McFarland W, Gibson S, Weide D, Henne J, Miller P, et al. Viagra use in a community-recruited sample of men who have sex with men, San Francisco.JAcquir Immune Defic Syndr 2003; 33:191-193.
84. Zona S, Guaraldi G, Luzi K, Beggi M, Santi D, Stentarelli C, et al. Erectile dysfunction is more common in young to middle-aged HIV-infected men than in HIV-uninfected men. J Sex Med 2012; 9:1923-1930.
85. Romanelli F, Smith KM. Recreational use of sildenafil by HIV-positive and-negative homosexual/bisexual males. Ann Phar-macother 2004; 38:1024-1030.
86. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99:168-177.
87. Geelen P, Drolet B, Rail J, Berube J, Daleau P, Rousseau G, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000; 102:275-277.
88. Norvir Summary of Product Characteristics. Abb Vie Limited. November 2014.
89. Kobayashi M, Takata Y, Goseki Y, Mizukami H, Hara S, Kuriiwa F, et al. A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardio-myopathy. Int J Cardiol 2015; 179:421-423.
90. Loulergue P, Gaillard R, Mir O. Interaction involving tadalafil and CYP3A4 inhibition by ritonavir. Scand J Infect Dis 2011; 43:239-240.
91. Intelence Summary of Product Characteristics. Janssen-Cilag Ltd. June 2014.